ANGN | Angion Biomedica Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0000 - 1.0000
52 Week Range	1.0000 - 20.40
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	224,803
Average Volume	9,772
Shares Outstanding	30,113,700
Market Cap	30,113,700
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.10
Forward P/E Ratio	N/A
EPS	-10.11
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

ANGN's peers: BNTC, EVAX, PHGE, PYPD

*Chart delayed

Analyzing fundamentals for ANGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ANGN Fundamentals page.

Watching at ANGN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ANGN Technicals page.